|Table of Contents|

Effects of celecoxib on gastric intestinal metaplasia in patients

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 19
Page:
3615-3621
Research Field:
Publishing date:

Info

Title:
Effects of celecoxib on gastric intestinal metaplasia in patients
Author(s):
ZHU Jiangyi1; LIU Jun1; SHI Yongquan1
1.Department of Gastroenterology；2.Department of Air Service,Xijing Hospital，Air Force Medical University，Shaanxi Xi'an 710032，China.
Keywords:
celecoxib; chronic atrophic gastritis; intestinal metaplasia; stomach neoplasms; malignancy risk
PACS:
R730.5
DOI:
10.3969/j.issn.1672-4992.2023.19.015
Abstract:
Objective:To assess the effectiveness of celecoxib for gastric intestinal metaplasia(IM)and to analyze factors associated with treatment failure.Methods:A total of 223 patients with gastric IM were retrospectively included in this study at our hospital from Apr. 1st 2019 to Jan. 1st 2022.All the patients received celecoxib therapy(200 mg/time，once a day) for 6 months.The efficacy was assessed by changes of theoperative link on the gastric intestinal metaplasia assessment(OLGIM) and the operative link on gastritis assessment(OLGA) staging system.Multivariate analysis was performed to analyze risk factors associated with treatment failure.Results:The effective rates for IM and atrophy were 49.8%(111/223) and 45.3%(101/223)，respectively.There were 50.4%(65/129) and 61.4%(43/70) of patients with higher OLGA and OLGIM stages reversed to lower stages，respectively.In addition，patients with higher OLGA and OLGIM stages showed a higher IM and atrophy regression rate than those with lower stages.The results of multivariate analysis showed that severe mucosal inflammatory status(inflammation score:3 to 4) was associated with treatment failure of celecoxib(OR=3.313，95%CI:1.359~8.076,P＜0.05).Conclusion:Celecoxib could reverse gastric IM and mucosal atrophy，which may further reduce the risk of gastric cancer.

References:

［1］SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
［2］CORREA P,PIAZUELO MB.Helicobacter pylori infection and gastric adenocarcinoma［J］.US Gastroenterol Hepatol Rev,2011,7(1):59-64.
［3］DINIS-RIBEIRO M,AREIA M,DE VRIES AC,et al.Management of precancerous conditions and lesions in the stomach(MAPS):guideline from the European Society of Gastrointestinal Endoscopy(ESGE),European Helicobacter Study Group(EHSG),European Society of Pathology(ESP),and the Sociedade Portuguesa de Endoscopia Digestiva(SPED)［J］.Endoscopy,2012,44(1):74-94.
［4］PIMENTEL-NUNES P,LIBNIO D,MARCOS-PINTO R,et al.Management of epithelial precancerous conditions and lesions in the stomach(MAPS II):European Society of Gastrointestinal Endoscopy(ESGE),European Helicobacter and Microbiota Study Group(EHMSG),European Society of Pathology(ESP),and Sociedade Portuguesa de Endoscopia Digestiva(SPED) guideline update 2019［J］.Endoscopy,2019,51(4):365-388.
［5］国家消化系疾病临床医学研究中心（上海）,国家消化道早癌防治中心联盟,中华医学会消化病学分会幽门螺杆菌学组,等.中国胃黏膜癌前状态和癌前病变的处理策略专家共识（2020年）［J］.中华消化杂志,2020,40(11):731-741. National Clinical Research Center For Digestive Disease(Shanghai),National Early Gastrointestinal-Center Prevention & Treatment Center Alliance,Helicobacter Pylori Group,et al.Chinese consensus on management of gastric epithelial precancerous conditions and lesions(2020)［J］.Chin J Dig,2020,40(11):731-741.
［6］HARA D,OKAMURA T,IWAYA Y,et al.Histopathologically defined intestinal metaplasia in lesser curvature of corpus prior to Helicobacter pylori eradication is a risk factor for gastric cancer development［J］.Helicobacter,2022,27(6):e12934.
［7］MALFERTHEINER P,MEGRAUD F,ROKKAS T,et al.Management of Helicobacter pylori infection:the maastricht VI/florence consensus report［J］.Gut,2017,66:6-30.
［8］CHENG HC,YANG YJ,YANG HB,et al.Evolution of the Correa's cascade steps:A long-term endoscopic surveillance among non-ulcer dyspepsia and gastric ulcer after H.pylori eradication［J］.J Formos Med Assoc,2023,122(5):400-410.
［9］LEE JWJ,ZHU F,SRIVASTAVA S,et al.Severity of gastric intestinal metaplasia predicts the risk of gastric cancer:a prospective multicentre cohort study(GCEP)［J］.Gut,2022,71(5):854-863.
［10］WU M,FENG S,QIAN M,et al.Helicobacter pylori infection combined with OLGA and OLGIM staging systems for risk assessment of gastric cancer:a retrospective study in Eastern China［J］.Risk Manag Healthc Policy,2022,15:2243-2255.
［11］OGUTMEN KOC D,KIMILOGLU E.Relation of cyclooxygenase-2 expression with premalignant gastric lesions［J］.Acta Gastroenterol Belg,2020,83(2):249-254.
［12］BENEDETTI I,HOYOS J,BARRIOS L.Cyclooxigenase-2 and osteopontin in gastric pre-neoplastic lesions in relation to H-pylori infection and grade of inflammation［J］.Rev Esp Patol,2020,53(2):79-87.
［13］HU ZL,HU YZ,JIANG HP.Overexpression of COX-2 and clinicopathological features of gastric cancer:a meta-analysis［J］.Transl Cancer Res,2020,9(4):2200-2209.
［14］HARRIS RE.Cyclooxygenase-2(COX-2)blockade in the chemoprevention of cancers of the colon,breast,prostate,and lung［J］.Inflammopharmacology,2009,17(2):55-67.
［15］HUNG KH,YANG HB,CHENG HC,et al.Short-term celecoxib to regress long-term persistent gastric intestinal metaplasia after Helicobacter pylori eradication［J］.J Gastroenterol Hepatol,2010,25(1):48-53.
［16］SHEU BS,TSAI YC,WU CT,et al.Long-term celecoxib can prevent the progression of persistent gastric intestinal metaplasia After H.pylori eradication［J］.Helicobacter,2013,18(2):117-123.
［17］YANG HB,CHENG HC,SHEU BS,et al.Chronic celecoxib users more often show regression of gastric intestinal metaplasia after Helicobacter pylori eradication［J］.Aliment Pharmacol Ther,2007,25(4):455-461.
［18］ZHANG LJ,WANG SY,HUO XH,et al.Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous lesions［J］.World J Gastroenterol,2009,15(22):2731-2738.
［19］WONG BC,ZHANG L,MA JL,et al.Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions［J］.Gut,2012,61(6):812-818.
［20］TYTGAT GN.The Sydney System:endoscopic division.Endoscopic appearances in gastritis/duodenitis［J］.J Gastroenterol Hepatol,1991,6(3):223-234.
［21］张贺军,金珠,崔荣丽,等.OLGA分期、分级评估系统在胃镜活检组织病理学评价中的应用［J］.中华消化内镜杂志,2014,31(3):121-125. ZHANG HJ,JIN Z,CUI RL,et al.Pathological assessment of gastric mucosa using OLGA system［J］.Chin J Dig Endosc,2014,31(3):121-125.
［22］NIIKURA R,HIRATA Y,HAYAKAWA Y,et al.Effect of aspirin use on gastric cancer incidence and survival:A systematic review and meta-analysis［J］.JGH Open,2019,4(2):117-125.
［23］LI B,CHEUNG KS,WONG IY,et al.Nonaspirin nonsteroidal anti-inflammatory drugs and gastric cancer risk after Helicobacter pylori eradication:A territory-wide study［J］.Cancer,2021,127(11):1805-1815.
［24］FANG S,FU Y,DU S,et al.The role of the endoscopic grading of gastric intestinal metaplasia in assessing gastric cancer risk:A systematic review and meta-analysis［J］.Front Oncol,2022,12:1018248.
［25］HUI Y,TU C,LIU D,et al.Risk factors for gastric cancer:A comprehensive analysis of observational studies［J］.Front Public Health,2023,10:892468.
［26］李健,马林科,闫晨薇,等.宁夏海原县胃癌癌前病变危险因素分析［J］.现代肿瘤医学,2021,29(14):2530-2535. LI J，MA LK，YAN CW，et al.Risk factors for precancerous lesions of gastric cancer in Haiyuan County,Ningxia［J］.Modern Oncology,2021,29(14):2530-2535.

Memo

Memo:
National Natural Science Foundation of China（No.82170560）;国家自然科学基金项目（编号：82170560）
Last Update: 2023-08-31